Managing intravascular complications following treatment with calcium hydroxylapatite: An expert consensus.
calcium hydroxylapatite
dermal filler
intra-arterial injection
safety
vascular compromise
vision loss
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
22
08
2019
accepted:
17
02
2020
pubmed:
19
3
2020
medline:
15
5
2021
entrez:
19
3
2020
Statut:
ppublish
Résumé
Inadvertent intra-arterial injection of dermal fillers including calcium hydroxylapatite (CaHA) can result in serious adverse events including soft tissue necrosis, permanent scarring, visual impairment, and blindness. When intra-arterial injection occurs, immediate action is required for optimal outcomes, but the infrequency of this event means that many physicians may never have experienced this scenario. The aim of this document is to provide evidence-based and expert opinion recommendations for the recognition and management of vascular compromise following inadvertent injection of CaHA. An international group of experts with experience in injection of CaHA and management of vascular complications was convened to develop a consensus on the optimal management of vascular compromise following intra-arterial CaHA injection. The consensus members were asked to provide preventative advice for the avoidance of intravascular injection and to produce a treatment protocol for acute and delayed presentation. To ensure all relevant treatment options were included, the recommendations were supplemented with a PubMed search of the literature. For prevention of intra-arterial CaHA injection, consensus members outlined the importance of a thorough knowledge of facial vascular anatomy and patient history, as well as highlighting potential risk zones and optimal injection techniques. Individual sections document how to recognize the symptoms of vascular occlusion leading to vision loss and tissue necrosis as well as detailed treatment protocols for the management of these events. For impending tissue necrosis, recommendations are provided for early and delayed presentations with treatment protocols for acute and follow-up treatment. A separate section details the treatment options for open and closed wounds. All physicians should be prepared for the eventuality of intra-arterial injection of a dermal filler, despite its rarity. These consensus recommendations combine advice from aesthetic experts with the latest reports from the published literature to provide an up-to-date office-based protocol for the prevention and treatment of complications arising from intra-arterial CaHA injection.
Sections du résumé
BACKGROUND
BACKGROUND
Inadvertent intra-arterial injection of dermal fillers including calcium hydroxylapatite (CaHA) can result in serious adverse events including soft tissue necrosis, permanent scarring, visual impairment, and blindness. When intra-arterial injection occurs, immediate action is required for optimal outcomes, but the infrequency of this event means that many physicians may never have experienced this scenario. The aim of this document is to provide evidence-based and expert opinion recommendations for the recognition and management of vascular compromise following inadvertent injection of CaHA.
METHODS
METHODS
An international group of experts with experience in injection of CaHA and management of vascular complications was convened to develop a consensus on the optimal management of vascular compromise following intra-arterial CaHA injection. The consensus members were asked to provide preventative advice for the avoidance of intravascular injection and to produce a treatment protocol for acute and delayed presentation. To ensure all relevant treatment options were included, the recommendations were supplemented with a PubMed search of the literature.
RESULTS
RESULTS
For prevention of intra-arterial CaHA injection, consensus members outlined the importance of a thorough knowledge of facial vascular anatomy and patient history, as well as highlighting potential risk zones and optimal injection techniques. Individual sections document how to recognize the symptoms of vascular occlusion leading to vision loss and tissue necrosis as well as detailed treatment protocols for the management of these events. For impending tissue necrosis, recommendations are provided for early and delayed presentations with treatment protocols for acute and follow-up treatment. A separate section details the treatment options for open and closed wounds.
CONCLUSIONS
CONCLUSIONS
All physicians should be prepared for the eventuality of intra-arterial injection of a dermal filler, despite its rarity. These consensus recommendations combine advice from aesthetic experts with the latest reports from the published literature to provide an up-to-date office-based protocol for the prevention and treatment of complications arising from intra-arterial CaHA injection.
Identifiants
pubmed: 32185876
doi: 10.1111/jocd.13353
pmc: PMC7687073
doi:
Substances chimiques
Dermal Fillers
0
Durapatite
91D9GV0Z28
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2845-2858Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals, Inc.
Références
Ophthalmic Plast Reconstr Surg. 2016 Mar-Apr;32(2):118-22
pubmed: 25794030
J Clin Aesthet Dermatol. 2018 May;11(5):E53-E55
pubmed: 29785240
Dermatol Surg. 2014 Aug;40(8):832-41
pubmed: 25022707
Dermatol Surg. 2006 Feb;32(2):276-81
pubmed: 16442055
Facial Plast Surg Clin North Am. 2013 Nov;21(4):663-73
pubmed: 24200384
Aesthet Surg J. 2010 Mar;30(2):235-8
pubmed: 20442101
Plast Reconstr Surg Glob Open. 2019 Mar 14;7(3):e2160
pubmed: 31044123
Ann Rheum Dis. 1985 Sep;44(9):614-20
pubmed: 3876080
J Clin Aesthet Dermatol. 2018 Jun;11(6):E61-E68
pubmed: 29942426
Clin Cosmet Investig Dermatol. 2018 Jul 16;11:357-363
pubmed: 30038511
Dermatol Surg. 2018 Nov;44 Suppl 1:S32-S41
pubmed: 30358631
Singapore Med J. 2016 Aug;57(8):438-43
pubmed: 27549227
Aesthet Surg J. 2013 May;33(4):561-75
pubmed: 23636629
Aesthet Surg J. 2017 Feb;37(2):203-208
pubmed: 27530765
Aesthetic Plast Surg. 2016 Jun;40(3):428-34
pubmed: 27102776
J Plast Reconstr Aesthet Surg. 2014 Apr;67(4):564-8
pubmed: 23993752
J Drugs Dermatol. 2017 Jan 1;16(1):68-74
pubmed: 28095536
Angiology. 2002 Jan-Feb;53 Suppl 1:S35-8
pubmed: 11865834
Dermatol Surg. 2009 Oct;35 Suppl 2:1672-80
pubmed: 19807763
J Cosmet Dermatol. 2018 Feb;17(1):39-46
pubmed: 28987016
J Plast Reconstr Aesthet Surg. 2018 Feb;71(2):162-170
pubmed: 29233508
Plast Reconstr Surg. 2019 Feb;143(2):416-426
pubmed: 30688884
Aesthet Surg J. 2014 May 1;34(4):584-600
pubmed: 24692598
Dermatol Surg. 2015 Dec;41 Suppl 1:S340-6
pubmed: 26618462
J Cosmet Dermatol. 2020 Nov;19(11):2845-2858
pubmed: 32185876
J Funct Biomater. 2018 Jan 18;9(1):
pubmed: 29346333
Int J Oral Maxillofac Surg. 2003 Aug;32(4):414-8
pubmed: 14505627
Plast Reconstr Surg. 2015 Nov;136(5 Suppl):204S-218S
pubmed: 26441101
Arch Plast Surg. 2012 Jan;39(1):51-4
pubmed: 22783492
J Clin Aesthet Dermatol. 2015 Jan;8(1):38-49
pubmed: 25610523
J Cosmet Dermatol. 2019 Jul 8;:
pubmed: 31282607
Dermatol Surg. 2017 Mar;43(3):464-467
pubmed: 28267701
J Cosmet Dermatol. 2018 Oct;17(5):712-718
pubmed: 30006992
BMC Ophthalmol. 2014 Oct 11;14:120
pubmed: 25306218
Plast Reconstr Surg. 2015 Nov;136(5 Suppl):219S-234S
pubmed: 26441102
Plast Reconstr Surg Glob Open. 2018 Sep 06;6(9):e1858
pubmed: 30349771
Plast Reconstr Surg. 2017 Apr;139(4):864e-872e
pubmed: 28350656
Plast Reconstr Surg. 2008 Apr;121(4):1421-9
pubmed: 18349665
Facial Plast Surg. 2016 Jun;32(3):253-60
pubmed: 27248022
Plast Reconstr Surg. 2019 Mar;143(3):504e-512e
pubmed: 30589824
Ann Plast Surg. 2015 Sep;75(3):258-60
pubmed: 26207560
Dermatol Surg. 2018 Jan;44(1):133-136
pubmed: 28445197
J Clin Aesthet Dermatol. 2012 May;5(5):44-7
pubmed: 22808309
Aesthet Surg J. 2017 Dec 13;38(1):73-88
pubmed: 27986754
Plast Reconstr Surg Glob Open. 2018 Dec 17;6(12):e2061
pubmed: 30656127
Aesthet Surg J. 2018 Jul 13;38(8):883-888
pubmed: 29506052
Aesthet Surg J. 2017 Jul 1;37(7):814-825
pubmed: 28333326
J Clin Aesthet Dermatol. 2015 Dec;8(12):42-7
pubmed: 26705447
Aesthet Surg J. 2013 Aug 1;33(6):862-77
pubmed: 23825309
JAMA Facial Plast Surg. 2018 May 1;20(3):207-214
pubmed: 29270603
Dermatol Surg. 2006 Mar;32(3):426-34
pubmed: 16640693
J Drugs Dermatol. 2007 Feb;6(2):123-8
pubmed: 17373169
J Clin Aesthet Dermatol. 2014 Sep;7(9):37-43
pubmed: 25276276
Dermatol Surg. 2015 Jul;41(7):841-7
pubmed: 26079591
Aesthet Surg J. 2015 Sep;35(7):844-9
pubmed: 25964629
Ann Plast Surg. 2011 Aug;67(2):184-8
pubmed: 21712695
Dermatol Surg. 2007 Dec;33 Suppl 2:S112-21; discussion S121
pubmed: 18086048
J Cosmet Dermatol. 2017 Jun;16(2):152-161
pubmed: 28247924
Dermatol Surg. 2018 Jan;44(1):75-83
pubmed: 28562435
Plast Reconstr Surg. 2012 Apr;129(4):995-1012
pubmed: 22456369
J Drugs Dermatol. 2011 Sep;10(9):1007-12
pubmed: 22052269
Dermatol Surg. 2014 Sep;40(9):1049-52
pubmed: 25077741
J Drugs Dermatol. 2017 Sep 1;16(9):866-872
pubmed: 28915281
J Cosmet Dermatol. 2018 Aug;17(4):625-631
pubmed: 30091282
J Cosmet Dermatol. 2018 Dec;17(6):1025-1030
pubmed: 30362225
J Cosmet Laser Ther. 2016;18(2):111-2
pubmed: 26052808
J Drugs Dermatol. 2013 Sep;12(9):996-1002
pubmed: 24002146
Plast Reconstr Surg. 2017 Jan;139(1):50e-58e
pubmed: 28027232
Laryngoscope. 1997 Mar;107(3):391-5
pubmed: 9121320
Plast Reconstr Surg Glob Open. 2018 Jan 11;6(1):e1618
pubmed: 29464158